ÖMER FARUK ELMAS, Mahmut Sami METİN, Okan KIZILYEL, Akın AKTAŞ, Canan BİRDAL

Kapesitabine bağlı gelişen bir palmoplantar dizestezi sendromu olgusu

Palmoplantar dizestezi sendromu kemoterapötiklerin kullanımına bağlı olarak gelişen dermatolojik toksik bir reaksiyondur. Elayak sendromu olarakta bilinir. Hayatı tehdit edici bir durum olmamasına rağmen hastaların yaşam kalitelerini önemli ölçüde azaltır. Klinik olarak hastalarda palmoplantar bölgede dizestezi, eritem, ödem ve deskuamasyon izlenir. Sitarabin, doksurubisin, kapesitabin, epirubisin, hidroksiüre, merkaptopürin, siklofosfamid, dosetaksel, vinorelbin ve 5-FU palmoplantar dizestezi sendromuna neden olabilen kemoterapötiklerdir. Olgumuz, metastatik meme karsinomu için kapesitabin tedavisi sırasında palmoplantar bölgede diffüz eritem ve deskuamasyon gelişen 62 yaşında bir kadın hastaydı. Kapesitabin tedavisi sonrası gelişen palmoplantar dizestezi sendromu hastanın tedaviye uyumunu etkilediği için olgumuzu sunduk.

A case of palmoplantar dysesthesia syndrome caused by capecitabine

Palmoplantar dysesthesia is a dermatologic toxic reaction caused by chemotherapeutics. Also known as hand-foot syndrome, it is not life-threatening, but does decrease quality of life. Dysesthesia, erythema, edema, and desquamation on palmoplantar region are observed clinically. Palmoplantar dysesthesia syndrome may be caused by chemotherapeutics including cytarabine, doxorubicin, capecitabine, epirubicin, docetaxel, vinorelbine, and 5-fluorouracil. The case of a 62-year-old woman who presented with diffuse erythema on palmoplantar area after use of capecitabine for metastatic breast carcinoma is described in the present report. Palmoplantar dysesthesia syndrome caused by capecitabine may affect patient compliance.

PDF

___

1. Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1(4):225-34.
2. Goutos I, Kaniorou-Larai M, Dziewulski P. "Hand-foot" syndrome-an unusual case of plantar pathology presenting to a burns unit. J Burn Care Res 2009;30(3):529-32.
3. Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):31-40.
4. Gökmen E. Chemotherapy in breast cancer. Turkiye Klinikleri J Med Oncol-Special Topics 2008;1(1):60-7.
5. Lee SD, Kim HJ, Hwang SJ, Kim YJ, Nam SH, Kim BS. Handfoot syndrome with scleroderma-like change induced by the oral capecitabine: a case report. Korean J Intern Med 2007;22(2):109-12.
6. Uslu G, Karaman G, Uslu M, Şavk E, Şendur N, Meydan N. Hand-foot Syndrome due tocapecitabine therapy: case report. Turkderm 2006;40(3):105-7.
7. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002;20(1):3-10.
8. Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355- 63.
9. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991;24(3):457-61.
10. Elasmar SA, Saad ED, Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol 2001;31(4):172-4.
11. Janusch M, Fischer M, Marsch WCh, Holzhausen HJ, Kegel T, Helmbold P. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy. Eur J Dermatol 2006;16(5):494-9.
12. Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006;6(3):219-23.
13. Gerbrecht BM. Current Canadian experience with capecitabine: partnering with patients to optimize therapy. Cancer Nurs 2003;26(2):161-7.